Business Type:
Trading Company
Business Range:
2-Methylimidazole, Sarms, Mk-2866, Peptide, Butyrolactone, Lidocaine, Benzocaine, ..
Establishment:
2018
R&D Capacity:
ODM, OEM, Other
Terms of Payment:
T/T, WesternUnion
Main Markets:
North America, South America, Europe, Southeast Asia, Middle East, East Asia(Japan, South Korea), Australia
OEM/ODM Service
Sample Available

CAS 110-63-4, 1 4-Butanediol, Bdo manufacturer / supplier in China, offering Organic Solvents CAS 110-63-4 1, 4-Butanediol/Bdo, Carisoprodol for Medical Use Muscle Relaxant CAS 78-44-4, High Quality Female Enhancer Powder Flibanserin 167933-07-5 Bimt 17 and so on.

1
    YRS
General Supplier
Supplier Homepage Chemicals Chemical Stocks High Quality Female Enhancer Powder Flibanserin 167933-07-5 Bimt 17

High Quality Female Enhancer Powder Flibanserin 167933-07-5 Bimt 17

Get Latest Price
Min. Order / Reference FOB Price
1 kg US $1.00/ kg
Local Area: Zhuzhou, Hunan, China
R&D Capacity: OEM, ODM, Other
Payment Terms: T/T, WesternUnion
CAS No.: 167933-07-5
Formula: C20h21f3n4o
EINECS: 259-415-2
High Quality Female Enhancer Powder Flibanserin 167933-07-5 Bimt 17FlibanserinBasic info:Product NameFlibanserinAliasBimt 17;BIMT 17 BSCAS167933-07-5MFC20H21F3N4OMW390.4AppearanceWhite Crystalline PowderAssay99%Packing1kg/foil bag or as reqiure
Standard
USP/BP
Price
Negotiated
Minimum order quantity
Negotiated
Package
Exquisite and can according to customers' requirement
Shipping leading time
Within 8hours after receiving the payment
Payment options
Western Union, MoneyGram, bank transfer (TT), Bitcoin
Shipping
Express delivery with DHL, EMS, Fedex, HKEMS, TNT, UPS (within 5-7days after payment)
Flibanserin
CAS: 167933-07-5
MF: C20H21F3N4O
MW: 390.4
Content: 99%
Appearance: white crystalline powder.
Catagory: Pharmaceutical raw material female sex enhanceCOA:ItemsSpecificationAppearancewhite crystals or crystalline powder, has afaint, characteristic odor and bitter tasteSolubilityfreely soluble in water and 95%ethanol, sparingly soluble in acetic anhydride and practically insoluble in diethyl etherPH3.5-4.5
Identification1, red to dark purple color appears with(III)iron chloride2, light red precipitate formed with reinecke salt TS3, UV spectrum meet the reference4, solution (1%) responds to the qualitative test for chlorideMelting point139-143 °CClarity and color of solutionclear and colorlessSulfate0.048%maxHeavy metals10ppm maxAs2ppm maxOrganic acid(0.1M NaOH)0.54ml maxLoss on drying0.5% maxResidue on ignition0.1%maxResidual organic Solvents (GC)Xylol 0.217%max
Related substances(HPLC)Isopropanol 0.5%maxTotal impurity 1.5%maxSingle impurity0.5%max
Count of bacteriaFree P-chloro phenoxy acetic 0.5%maxbacillus 1000/1g maxMildew 100/1g maxMicrozyme 100/1g max
Description:
Flibanserin is adrug developed to treat hypoactive sexual desire disorder (HSDD) in women. Women with HSDD have achronic lack of interest in sex that cannot be explained by another medical condition. HSDD is also accompanied by feelings of distress.
Flibanserin is anovel, non-hormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire.
More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine and decreasing serotonin. In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss.Applications:
A new drug designed to boost sexual desire in women is controversial for some and eagerly awaited by others, but it's hit apotentially serious snag. The drug didn't boost women's desire any more than aplacebo in two clinical trials.
The Food and Drug Administration posted the clinical trial results on its website today in advance of acommittee meeting on Friday, when apanel of experts will vote whether or not to recommend approval of the drug called flibanserin.
Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report a0.5 increase compared to placebo in the number of times they had "satisfying sexual events". In those on flibanserin it rose from 2.8 to 4.5 times amonth while women receiving placebo reported also an increase of "satisfying sexual events" from 2.7 to 3.7 times amonth. The onset of the flibanserin effect was seen from the first timepoint measured after 4weeks of treatment and maintained throughout the treatment period.
Related products lists:Pain KillerBenzocaine /Benzocaine hclTetracaine /Tetracaine HCLProcaine /Procaine HclBupivacaine/ Bupivacaine HCLLidocaine HCLArticaine /Articaine hclClomiphene citrate (Clomid)Letrazole(Femara /For mestane)Exe mestane(Aromasin)PharmaceuticalsPhe nacetinRaloxifene HCLTheophyllineDexamethasone Sodium PhosphateFura zabol THPParacetamolAtorvastatin CalciumPregabalinLorcaserinCarbergolineSafe Organic SolventsGamma-Butyrolactones(GBLsolvents )Benzyl Alcohol(BA)1,4-Butanediol(BDO)Benzyl benzoate(BB)Ethyl Oleate(EO)GuaiacolGrape Seed Oil(GSO)Poly Ethylene Glycol(PEG)Polysorbate 80MGF PEG MGFHexarelin 2mg/vialCJC-1295 /with DACSermorelin 2mg/vialPT-141 10mg/vialSelank 5mg/vialMT-1 MT-2 10mg/vialFollistatin 344GHRP-2 5mg/vial &10mg/vialFollistatin 315GHRP-6 5mg/vial &10mg/vialEptifibatideSARMsAicarMK-2866/Ostarine/EnobosarmAndarine /S4RAD-140Andarine /GTX-007SR9011GW-501516(cardarine)SR9009LGD-4033SunifiramMK-677/Ibutamoren/NutrobalYK11